Jubilant Pharmova Ltd.

NSE: JUBLPHARMA BSE: 530019 SECTOR: Pharmaceuticals & Drugs  75k   443   83

278.70
+7.05 (2.60%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 282.05

Today's Low

₹ 268.8

52 Week High

₹ 495.55

52 Week Low

₹ 268.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4439.17 Cr.

Enterprise Value

4915.66 Cr.

No. of Shares

15.93 Cr.

P/E

57.18

P/B

1.82

Face Value

₹ 1

Div. Yield

1.77 %

Book Value (TTM)

₹  153.25

CASH

22.51 Cr.

DEBT

499 Cr.

Promoter Holding

50.68 %

EPS (TTM)

₹  4.87

Sales Growth

-96.76%

ROE

6.12 %

ROCE

6.35%

Profit Growth

-63.4 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-96.76%
3 Year-70.56%
5 Year-48.79%

Profit Growth

1 Year-63.4%
3 Year-18.98%
5 Year-0.18%

ROE%

1 Year6.12%
3 Year10.04%
5 Year9.77%

ROCE %

1 Year6.35%
3 Year9.42%
5 Year9.99%

Debt/Equity

0.3894

Price to Cash Flow

-1249.77

Interest Cover Ratio

3.68916135360471

CFO/PAT (5 Yr. Avg.)

1.62035269525386

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 50.68 0
Sep 2022 50.68 0
Jun 2022 50.68 0
Mar 2022 50.68 0
Dec 2021 50.68 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 88.3257738068104 days.
  • The company has a high promoter holding of 50.68%.

 Limitations

  • The company has shown a poor profit growth of -18.9840470717146% for the Past 3 years.
  • The company has shown a poor revenue growth of -70.55907893862% for the Past 3 years.
  • Company has negative cash flow from operations of -3.552.
  • The company is trading at a high PE of 57.18.
  • The company is trading at a high EV/EBITDA of 37.9953.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 155.47 28.79 204.57 222.97 182.74
Total Expenditure 173.29 30.38 208.94 215.67 184.63
Operating Profit -17.82 -1.59 -4.37 7.3 -1.89
Other Income 8.55 7.1 10.24 106.12 7.87
Interest 2.74 8.06 3.15 4.14 5.53
Depreciation 9.23 1.59 9.21 11.08 11.59
Exceptional Items 0 0 0 0 0
Profit Before Tax -21.24 -4.14 -6.49 98.2 -11.14
Tax -5.64 -1.03 -1.31 6.39 -5.25
Profit After Tax -15.6 -3.11 -5.18 91.81 -5.89
Adjusted EPS (Rs) -0.98 -0.2 -0.33 5.76 -0.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 3306.32 3438.61 3139.9 2709.5 87.75
Total Expenditure 2767.08 3117.74 2769 2282.44 94.54
Operating Profit 539.25 320.88 370.9 427.06 -6.79
Other Income 46.21 78 173.23 47.88 125.87
Interest 135.17 128.96 136.2 101.8 30.59
Depreciation 82.6 86.48 107.4 99.97 6.25
Exceptional Items 0 0 -1.7 0 0
Profit Before Tax 367.69 183.43 298.84 273.17 82.25
Tax 104.25 35.8 -22.3 58.69 3.75
Net Profit 263.44 147.63 321.14 214.48 78.5
Adjusted EPS (Rs.) 16.54 9.27 20.16 13.47 4.93

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 15.93 15.93 15.93 15.93 15.93
Total Reserves 2233.45 2324.38 2591.37 1266.52 1265.89
Borrowings 1059.38 1139.57 1327.91 420 499
Other N/C liabilities 77.3 86.01 122.95 22 10.97
Current liabilities 1238.48 1297.74 1375.23 120.15 37.68
Total Liabilities 4624.54 4863.63 5433.39 1844.6 1829.47
Assets
Net Block 1437.81 1491.35 1864.72 127.08 123.54
Capital WIP 115.32 283.82 58.41 0.33 0.06
Intangible WIP 0 0 0.68 0 0
Investments 1706.3 1763.89 1764.03 1645.98 1645.75
Loans & Advances 12.27 18.02 16.03 4.96 9.3
Other N/C Assets 26.95 25.38 7.39 0 2.92
Current Assets 1325.89 1281.17 1722.13 66.25 47.9
Total Assets 4624.54 4863.63 5433.39 1844.6 1829.47
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 367.69 183.43 298.84 273.17 82.25
Adjustment 206.69 159.26 103.01 196.45 -60.64
Changes in Assets & Liabilities 41.63 -112.03 -65.06 181.36 -5.78
Tax Paid -58.17 -48.93 -20.03 -42.6 -19.38
Operating Cash Flow 557.85 181.74 316.76 608.38 -3.55
Investing Cash Flow -126.93 -284.79 -197.71 116.89 93.1
Financing Cash Flow -470.44 85.28 -41.05 -781.65 -107.37
Net Cash Flow -39.52 -17.77 78 -56.37 -17.82

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 50.68 50.68 50.68 50.68 50.68
jubilant stock hol... 13.73 13.73 13.41 13.41 13.41
ssb consultants an... - - - 13.55 13.55
ssb consultants an... 13.19 13.19 13.55 - -
hsb corporate cons... - - - 12.10 12.10
hsb corporate cons... 11.74 11.74 12.10 - -
mav management adv... 3.34 3.34 3.15 3.15 3.15
jubilant consumer ... 1.78 1.78 - - -
miller holdings pt... - - 3.28 3.28 3.28
nikita resources p... 2.20 2.20 2.20 2.20 2.20
jubilant enpro pri... - - 1.78 1.78 1.78
cumin investments ... 1.51 1.51 - - -
rance investment h... 1.51 1.51 - - -
jubilant advisors ... - - - - -
shyam sunder bhart... 0.88 0.88 0.88 0.88 0.88
torino overseas li... 0.48 0.48 - - -
hari shanker bhart... 0.23 0.23 0.23 - -
hari shankar bhart... - - - 0.23 0.23
shamit bhartia 0.08 0.08 0.08 0.08 0.08
kavita bhartia 0.01 0.01 0.01 0.01 0.01
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 49.32 49.32 49.32 49.32 49.32
rakesh radheshyam ... 1.57 1.88 3.45 4.41 5.11
east bridge capita... 4.63 4.63 4.63 4.63 4.63
government pension... 1.56 1.76 3.00 3.05 3.03
motilal oswal mutu... 2.70 2.67 - - -
east bridge capita... - - - - 3.37
east bridge capita... - - 1.10 3.37 -
lazard emerging ma... 1.13 1.21 1.30 1.78 1.08
morgan stanley asi... 1.24 1.24 1.02 - -
iepf 0.51 0.66 0.65 1.24 1.24
dsp top 100 equity... - - 1.22 1.22 1.10
bnp paribas arbitr... - - 1.10 - -
jll-unclaimed susp... - - - - -
investor education... - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Jubilant Pharmova’s arm gets additional loan facility from Government of Canada17 Mar 2023, 4:49PM Jubilant Pharmova informs about communication17 Mar 2023, 10:06AM USFDA classifies Jubilant Pharmova’s API Facility as VAI8 Mar 2023, 3:58PM Jubilant Pharmova informs about appointment of statutory auditors4 Feb 2023, 2:14PM Jubilant Pharmova reports consolidated net loss of Rs 16 crore in Q3FY23 3 Feb 2023, 3:59PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova informs about investor conference call1 Feb 2023, 4:42PM Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Mertiatide Injection1 Feb 2023, 9:47AM Jubilant Pharmova informs about credit rating 27 Dec 2022, 4:30PM Jubilant Pharmova informs about closure of trading window23 Dec 2022, 4:37PM USFDA concludes inspection at Jubilant Pharmova’s API manufacturing facility in Nanjangud14 Dec 2022, 3:30PM Jubilant Pharmova informs about granted stock options17 Nov 2022, 5:02PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova informs about USFDA communication27 Aug 2022, 11:52AM Jubilant Pharmova’s arm gets EIR from USFDA for radiopharmaceuticals manufacturing facility Montreal Canada 27 Aug 2022, 10:06AM USFDA completes audit at Jubilant Pharmova’s step down subsidiary's facility 3 Aug 2022, 11:14AM Jubilant Pharmova informs about outcome of board meeting2 Aug 2022, 2:35PM Jubilant Pharmova - Quaterly Results2 Aug 2022, 12:58PM Jubilant Pharmova - Quaterly Results2 Aug 2022, 12:58PM Jubilant Pharmova - Quaterly Results2 Aug 2022, 12:58PM Jubilant Pharmova informs about record date29 Jul 2022, 3:32PM Jubilant Pharmova’s arm enters into loan agreement with Standard Chartered Bank14 Jul 2022, 9:22AM Jubilant Pharmova’s arm inks pact with US Government to expand critical vaccine manufacturing capacity 30 May 2022, 10:45AM Jubilant Pharmova informs about audio recording of investor conference call 28 May 2022, 1:26PM Jubilant Pharmova - Quaterly Results27 May 2022, 4:30PM Jubilant Pharmova - Quaterly Results27 May 2022, 4:30PM Jubilant Pharmova - Quaterly Results27 May 2022, 4:30PM Jubilant Pharmova informs about analyst meet5 Apr 2022, 10:17AM Jubilant Pharmova enters into agreements to acquire stake in SPV Laboratories4 Apr 2022, 2:38PM Jubilant Pharmova informs about acquisition2 Apr 2022, 3:01PM Jubilant Pharmova informs about loss of share certificates25 Feb 2022, 12:40PM Jubilant Pharmova - Quaterly Results4 Feb 2022, 3:32PM Jubilant Pharmova - Quaterly Results4 Feb 2022, 3:32PM Jubilant Pharmova - Quaterly Results4 Feb 2022, 3:32PM Jubilant Pharmova inform about conference call27 Jan 2022, 2:40PM Jubilant Pharmova informs about loss of share certificates19 Jan 2022, 3:31PM Jubilant Pharmova informs about analyst meet15 Nov 2021, 4:54PM Jubilant Pharmova submits newspaper publication25 Oct 2021, 12:38PM Jubilant Pharmova - Quaterly Results22 Oct 2021, 2:57PM Jubilant Pharmova informs about press release26 Jul 2021, 10:15AM Jubilant Pharmova reports 82% rise in Q1 consolidated net profit24 Jul 2021, 12:04PM Jubilant Pharmova informs about outcome of committee meeting24 Jul 2021, 11:05AM USFDA issues import alert on Jubilant Pharmova’s Roorkee manufacturing facility16 Jul 2021, 11:47AM Jubilant Pharmova informs about confirmation certificate9 Jul 2021, 10:14AM Jubilant Pharmova submits disclosure of related party transactions29 Jun 2021, 4:58PM Jubilant Pharmova informs about analyst meet23 Jun 2021, 2:53PM

Jubilant Pharmova Stock Price Analysis and Quick Research Report. Is Jubilant Pharmova an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jubilant Pharmova and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -3.552 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jubilant Pharmova has a Debt to Equity ratio of 0.3894 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jubilant Pharmova , the EPS growth was -63.3977705658248 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jubilant Pharmova has OPM of -7.7346492227743 % which is a bad sign for profitability.
     
  • ROE: Jubilant Pharmova have a poor ROE of 6.12404500728031 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Jubilant Pharmova

X